8-K filing — Amylyx Pharmaceuticals, Inc. (AMLX)
Filed: 2026-09-08 AccNo: 0001193125-26-385331 Size: 147 KB Item 1.01: Entry into a Material Definitive Agreement
Stocks · News reference
Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday
US stocks down, Nasdaq falls 300+ points. Duos Tech shares rise on better Q2 results. Many other big stocks gain, including Duolingo, Intuit, and Newsmax.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Amylyx Pharmaceuticals has surged 247% in 2026 following positive Phase 3 trial results for avexitide, its experimental treatment for post-bariatric hypoglycemia. With no current FDA-approved treatments for PBH and potential peak sales of $1.5 billion, the stock shows promise but may have already priced in much of the upside. The analyst suggests waiting for a pullback to $28-$30 per share for a better entry point.
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57
Benzinga Bulls and Bears: Ross, Moderna, Webull
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
This Ormat Technologies Analyst Is No Longer Bearish; Here Are Top 3 Upgrades For Friday
Analysts upgraded ORA, WPC, and more with higher price targets.
This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Analysts upgraded Alumis, Sirius XM, OGE Energy, revising their price targets and outlooks.